Leap Therapeutics, Inc. (NASDAQ:LPTX), a biopharmaceutical company, announced the results of its 2024 Annual Meeting of Stockholders held on Monday. Shareholders elected four Class I directors to serve until the 2027 annual meeting and approved all proposals on the ballot, including the executive compensation plan and an amendment to the company's equity incentive plan.
The elected directors are James Cavanaugh, Douglas E. Onsi, Christian Richard, and Richard Schilsky. Votes for the directors ranged from 16,740,789 to 17,809,064, with votes withheld spanning from 323,797 to 1,392,072. Broker non-votes for all directors were reported at 7,871,104.
In the advisory vote on executive compensation, the proposal received 16,820,682 votes for, 1,272,059 against, and 40,120 abstentions, with 7,871,104 broker non-votes. The amendment to the Leap Therapeutics, Inc. 2022 Equity Incentive Plan was approved with 16,572,103 votes for, 1,480,150 against, and 80,608 abstentions, accompanied by the same number of broker non-votes.
Additionally, the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified with substantial support, receiving 25,894,496 votes for, 71,613 against, and 37,856 abstentions.
The meeting, which took place at the company's headquarters in Cambridge, MA, follows Leap Therapeutics' continued focus on developing novel therapeutics. The company, incorporated in Delaware and part of the pharmaceutical preparations industry, is known for its efforts in the field of oncology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.